WOS: 000268915900016PubMed ID: 19079149Aims To determine the short-term effect of intravitreal bevacizumab administration on systemic blood pressure levels of patients and to evaluate the safety of the drug in these patients. Methods Study population was divided into two groups: group A comprised patients who had hypertension and were under medication with antihypertensive drugs; group B comprised patients with normal blood pressure and were not under medication with antihypertensive drugs. All patients were graded according to their blood pressure levels before single dose of bevacizumab (0.05 ml; 1.25 mg) injection, and at day 1 and weeks 1, 3, and 6 thereafter. The blood pressure levels were analysed using repeated measures of analysis o...
WOS: 000401036900003PubMed ID: 28060360Purpose To evaluate effects of intravitreal ranibizumab and b...
PURPOSE: To report the 6-month anatomical and visual outcomes after injecting two different doses of...
PURPOSE: To investigate plasma and vitreous vascular endothelial growth factor (VEGF) levels after i...
Objectives: To evaluate the short-term intraocular pressure (IOP) changes after intravitreal injecti...
Background To evaluate the effect of intra-vitreal injection of Bevacizumab on Intra-ocular pressure...
Purpose To determine the short-term changes in systemic arterial blood pressure (SABP) during intrav...
Background Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the...
PURPOSE: To investigate the short-term effects of panretinal photocoagulation (PRP) combined with an...
PURPOSE: To evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic r...
Exudative age-related macular degeneration is the most common cause of vision loss of people over th...
PURPOSE: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular...
Background and Objective: Central serous retinopathy (CSR) is an idiopathic retinal disease that cau...
Introduction: Bevacizumab (Avastin) is considered as an effective strategy in the treatment of vario...
PURPOSE: The aim of the this study was to determine the effect of intravitreal antivascular endothel...
Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of...
WOS: 000401036900003PubMed ID: 28060360Purpose To evaluate effects of intravitreal ranibizumab and b...
PURPOSE: To report the 6-month anatomical and visual outcomes after injecting two different doses of...
PURPOSE: To investigate plasma and vitreous vascular endothelial growth factor (VEGF) levels after i...
Objectives: To evaluate the short-term intraocular pressure (IOP) changes after intravitreal injecti...
Background To evaluate the effect of intra-vitreal injection of Bevacizumab on Intra-ocular pressure...
Purpose To determine the short-term changes in systemic arterial blood pressure (SABP) during intrav...
Background Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the...
PURPOSE: To investigate the short-term effects of panretinal photocoagulation (PRP) combined with an...
PURPOSE: To evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic r...
Exudative age-related macular degeneration is the most common cause of vision loss of people over th...
PURPOSE: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular...
Background and Objective: Central serous retinopathy (CSR) is an idiopathic retinal disease that cau...
Introduction: Bevacizumab (Avastin) is considered as an effective strategy in the treatment of vario...
PURPOSE: The aim of the this study was to determine the effect of intravitreal antivascular endothel...
Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of...
WOS: 000401036900003PubMed ID: 28060360Purpose To evaluate effects of intravitreal ranibizumab and b...
PURPOSE: To report the 6-month anatomical and visual outcomes after injecting two different doses of...
PURPOSE: To investigate plasma and vitreous vascular endothelial growth factor (VEGF) levels after i...